CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...